Big shot: Andrew Leaver

Share via

The imminent flotation of Clinigen may breathe life into Britain’s moribund IPO market but it also marks the exit of the company’s founder, Andrew Leaver.

Mr Leaver established the company in 2007 when he formed Clinigen Healthcare, but the business in its current form took shape in 2010 when it acquired the Foscavir antiviral medicine that is used to treat HIV and Aids-related illnesses from AstraZeneca. Mr Leaver, an industry veteran, will bank about £75 million if the £170 million float on AIM is successful.

He holds a 64 per cent stake in the business but will sell the majority